Abstract：ObjectiveTo explore the Leflunomide combined with glucocorticoid on treating advanced IgA nephropathy and its influence on VCAM-1 level.MethodsFrom March 2015 to January 2017,108 advanced IgA nephropathy patients treated in our hospital were selected as research objects.According to their different therapeutic time,they were evenly divided into the treatment group and the control group,54 cases in each group.In the treatment group,Leflunomide combined with glucocorticoid was used,while in the control group,Prednisolone was applied.The therapeutic effect, detection indicators like serum,etc.,and adverse reactions after treatment in the two groups were recorded.ResultsAfter treatment,the total effective rate was 92.59%in the treatment group,which was higher than that in the control group (75.98%)(P＜0.05).After treatment,the urine protein content,serumalbumin content,serum creatinine content,glomerular filtration rate,and the level of VCAM-1 all tended to normal values,which were displayed statistical differences compared with before treatment(P＜0.05).There was significant difference in the urine protein content,serumalbumin content,serum creatinine content,glomerular filtration rate,and the level of VCAM-1 between the two groups after treatment(P＜0.05).The total adverse reaction rate in the treatment group was 18.52%,and 24.07%in the control group,there was no significant difference (P＞0.05).ConclusionCombination of Leflunomide and glucocorticoid in the treatment of progressive IgA nephropathy is effective,and it is helpful for the self-recovery of these patients and can greatly decrease VCAM-1 level.It is worthy to be promoted in clinical practice,which has a remarkable medical value and is of great significance.
时蔡林. 来氟米特联合糖皮质激素治疗进展性IgA肾病的效果及对VCAM-1水平的影响[J]. 中国当代医药, 2017, 24(31): 80-82.
SHI Cai-lin. Effect of Leflunomide combined with glucocorticoid in the treatment of advanced IgA nephropathy and its influence on VCAM-1 level. 中国当代医药, 2017, 24(31): 80-82.
京公网安备 11010502046607号